NCT00629343View on ClinicalTrials.gov

Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Soft Tissue SarcomaMesothelioma
Interventions
DRUG

Azacitidine

Azacitidine will be delivered sub-cutaneously for 5 days

DRUG

Temozolomide

Temozolomide will be given starting on day 8 for 5 days at a dose of 200 mg/m2 po qd x 5 days

Trial Locations (1)

10032

Columbia University Medical Center, New York

Sponsors
All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

collaborator

Celgene Corporation

INDUSTRY

lead

Columbia University

OTHER